Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Heavy metal Stories

2013-10-09 16:21:21

CARLSBAD, Calif., Oct. 9, 2013 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2013 Distinguished Scientist Award by the San Diego section of the American Chemical Society (ACS). The award recognizes Dr. Crooke's contributions in leading Isis Pharmaceuticals, a long-standing leader in drug discovery in the San Diego community. Isis' innovative RNA-based drug...

2013-10-07 12:26:07

KISS Front Man to Be Special Guest on Google+ Hangout to Benefit Mending Kids International LOS ANGELES, Oct. 7, 2013 /PRNewswire/ -- Gene Simmons, legendary bass guitarist and lead singer of KISS, will be the special guest at a Google+ Hangout on Friday, October 11 at 10AM Pacific time. To access the "Hangout," visitors should go to www.mendingkids.org/hangoutwithgene. The interview will be conducted by MKI Board member and renowned broadcast journalist Dorothy Lucey. The...

2013-10-07 08:24:46

CARLSBAD, Calif., Oct. 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that GlaxoSmithKline (GSK) has added a development candidate ISIS-GSK3(Rx), to its collaboration with Isis. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3(Rx) is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3(Rx) to Phase 2...

2013-10-03 16:23:10

--Isis earns $2 million milestone payment-- CARLSBAD, Calif., Oct. 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it dosed the first infant in the 12 mg dose group in the Phase 2 study evaluating ISIS-SMN(Rx) in infants with Type I spinal muscular atrophy (SMA). The Phase 2 study is designed to allow Isis to define the optimal dose for the larger Phase 2/3 study in infants and to provide safety and tolerability data. Isis plans to complete...

2013-09-25 08:29:05

CARLSBAD, Calif., Sept. 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Leerink Swann Rare Disease Roundtable on Wednesday, October 2, 2013 at 2:20 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's...

2013-09-24 08:38:09

B2B integration software provider promotes company veteran to manage product framework POTTSVILLE, Pa., Sept. 24, 2013 /PRNewswire/ -- EXTOL International, a leading provider of business integration software and services, names long-time employee, Jeffrey Inns as the company's Vice President, Product Infrastructure. In this role, Inns manages product training, product management, and documentation. A company veteran, Inns has been with EXTOL since 2000 and has served the company in...

2013-09-22 08:20:22

CARLSBAD, Calif., Sept. 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that Isis will conduct a live webcast and slide presentation conference call at 11:30 a.m. Eastern Time on Monday, September 23 to discuss ISIS-APOCIII(Rx) Phase 2 data in patients with familial chylomicronemia syndrome. These data were presented on Saturday, September 21, 2013 at the National Lipid Association clinical lipid update...

2013-09-18 16:26:18

CARLSBAD, Calif., Sept. 18, 2013 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2013 Director of the Year Award for Companies in Transition. Each year the Corporate Directors Forum, a non-profit organization that promotes high standards of professionalism in corporate governance, recognizes directors for their high standards in corporate governance. Dr. Crooke is...

2013-09-05 08:28:18

CARLSBAD, Calif., Sept. 5, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 Stifel Healthcare Conference on Wednesday, September 11, 2013 at 1:30 p.m. ET in Boston, MA. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2013-09-04 08:30:34

CARLSBAD, Calif., Sept. 4, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 2:05 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's...


Latest Heavy metal Reference Libraries

Brilliant Emerald, Somatochlora metallica
2013-07-30 14:54:37

The brilliant emerald (Somatochlora metallica) is a species of dragonfly that can be found in northern areas of Eurasia. Its range includes Austria, Belgium, Croatia, Denmark, France, Germany, Norway, Serbia, Sweden, and the United Kingdom, among many other areas. This species prefers to reside near still and slow-moving water sources like rivers, canals, ponds, and moorland lakes. It is common in most areas of its range, but its total population number and population trend is unknown. It is...

More Articles (1 articles) »